Evidence map›Paper›PMID 41251091›Full record

ArticleChembiochem : a European journal of chemical biology2025

Synthesis of the Abiraterone Derivatives 5α- and 5β-Δ

Noboru Hayama, Shizuyo Horiyama, Ryoma Okamoto, Yukina Nishi, Manae Yada, Ryuji Higashida, Jun Haginaka, Yoshihide Usami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthesis of the Abiraterone Derivatives 5α- and 5β-ΔChembiochem : a European journal of chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noboru HayamaFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.ORCID https://orcid.org/0000-0003-1532-5249
Shizuyo HoriyamaSchool of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan.ORCID https://orcid.org/0000-0002-8899-3451
Ryoma OkamotoFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
Yukina NishiFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
Manae YadaFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
Ryuji HigashidaFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
Jun HaginakaInstitute for Biosciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan.ORCID https://orcid.org/0000-0001-6760-7745
Yoshihide UsamiFaculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.ORCID https://orcid.org/0000-0002-6475-048X

Funding

Japan Society for the Promotion of Science JP22K06571
6 · The paper itself

Abstract

Abiraterone (Abi) acetate, an anticancer drug, produces metabolites in the serum of patients with prostate cancer. Three unknown metabolites of Abi are previously discovered and the structures of two of these compounds are determined by comparing their LC-based retention times with those of synthesized compounds. However, the structure of the third metabolite is not identified. Herein, two new Abi derivatives, 5α-Δ

Indexed as

Abiraterone AcetateAndrostenesAntineoplastic AgentsAdministration, OralHumansMaleMolecular StructureProstatic NeoplasmsabirateroneAbiraterone AcetateAndrostenesAntineoplastic Agentsabirateronemetaboliteolefinationprostate cancersteroid

Identifiers

PMID41251091
PMCPMC12703417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.